Evaluating the efficacy of seasonal influenza vaccine in pemphigus Patients
Not Applicable
Recruiting
- Conditions
- Pemphigus vulgarisPemphigus disease.L10.0
- Registration Number
- IRCT20191022045185N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
pemphigus Patients
Patients treated with minimal dose therapy (disease in control phase)
A history of receiving a biological drug more than six months ago
Exclusion Criteria
The patient is in the active phase of the disease
Be treated with high doses of the drug
received a biological drug six months ago
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of the effectiveness of seasonal influenza vaccine in relapse rate of pemphigus in patients under control of pemphigus. Timepoint: before and every three month. Method of measurement: PDAI ,Dsg1/3.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What immune response pathways are modulated by seasonal influenza vaccine in pemphigus vulgaris patients?
How does seasonal influenza vaccination compare to standard corticosteroid therapy in reducing pemphigus flares?
Which biomarkers correlate with vaccine efficacy in pemphigus patients with ICD-10 L10.0 classification?
What adverse events are reported in pemphigus patients receiving seasonal influenza vaccine during immunosuppressive therapy?
Are adjuvant strategies or combination vaccines being explored for pemphigus disease management alongside standard immunosuppressants?